Record fundraising brings Forbion’s assets under management to approximately €7.5 billion
Het Financieele Dagblad’s article “Forbion haalt €2,3 mrd op en wordt grootste Europese investeerder in biotech” covers Forbion’s largest fundraising to date: €2.3 billion raised across Forbion Growth Opportunities Fund IV and Forbion Ventures Fund VIII. The new capital increases the Naarden-based firm’s assets under management to approximately €7.5 billion and, based on Preqin data, establishes Forbion as Europe’s largest dedicated life sciences venture capital firm by assets under management.
The article places the announcement in the context of Forbion’s continued growth, following the approximately €2.1 billion raised for its predecessor funds in 2024. Together, the two new funds have the capacity to finance around 30 high-potential biotech companies. Growth Opportunities Fund IV will focus primarily on later-stage biopharma companies in Europe and North America, while Ventures Fund VIII will invest in therapeutics-focused biotech companies, including existing businesses and new ventures built around promising science and experienced teams.